Avapritinib for treatment of GIST (New Drug 2020)
Avapritinib is a PDGFRA (Plateket Derived Growth Factor Receptor Alpha) kinase inhibitor approved for treatment of unresectable or metastatic GIST (Gastro Intestinal Stromal Tumor) which is positive for PDGFRA exon 18 mutation.
Dose is 300 mg OD by oral route.
Side-effects associated are intracranial hemorrhage, neurotoxicity and teratogenicity.
Current treatment of GIST is surgical removal along with radiotherapy and chenmotherapy with doxorubicin and ifosfamide.
